Diagnosis and Management of Pancreatic Cancer

Overview

Journal CMAJ

Date 2013 Apr 24

PMID 23610017

Citations 26

Authors

Zaheer S Kanji

Steven Gallinger

Affiliations

Soon will be listed here.

Citing Articles

Diagnostic Value of Cytology in Pancreatic Endoscopic Ultrasound-Guided Fine Needle Aspiration: Accuracy in Common Epithelial Pancreatobiliary Tumors and the Role of Cell Block Analysis.

Rakhshani N, Soleimani N, Aghaei S, Barakat R, Keshtvarz Hesam Abadi A Iran J Pathol. 2025; 20(1):98-107.

PMID: 40060228 PMC: 11887639. DOI: 10.30699/ijp.2024.2036290.3329.

Development and Validation of a Survival Prediction Model for Patients With Pancreatic Cancer.

James P, Almousawi F, Salim M, Khan R, Tanuseputro P, Hsu A Clin Transl Gastroenterol. 2024; 16(1):e00774.

PMID: 39620578 PMC: 11756872. DOI: 10.14309/ctg.0000000000000774.

Diffuse Type Pancreatic Ductal Adenocarcinoma: The Linitis Plastica Type of the Pancreas.

Radwan M, Darawsha B, Mansour S, Khuri S J Med Cases. 2024; 15(12):406-410.

PMID: 39610910 PMC: 11602175. DOI: 10.14740/jmc5062.

Palliative Stenting for Gastric Outlet Obstruction Secondary to Pancreatic Adenocarcinoma.

Patel D, Bhullar F, Tagliaferri A, Melki G, Grossman M Cureus. 2024; 16(1):e53186.

PMID: 38425636 PMC: 10901673. DOI: 10.7759/cureus.53186.

Role of Therapeutic Endoscopic Ultrasound in Management of Pancreatic Cancer: An Endoscopic Oncologist Perspective.

Dahiya D, Chandan S, Ali H, Pinnam B, Gangwani M, Al Bunni H Cancers (Basel). 2023; 15(12).

PMID: 37370843 PMC: 10296171. DOI: 10.3390/cancers15123235.

References

Van Der Gaag N, Rauws E, van Eijck C, Bruno M, van der Harst E, Kubben F . Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010; 362(2):129-37. DOI: 10.1056/NEJMoa0903230. View

Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos J, Ghaneh P . Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007; 25(18):2607-15. DOI: 10.1200/JCO.2006.09.2551. View

Canto M, Goggins M, Hruban R, Petersen G, Giardiello F, Yeo C . Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006; 4(6):766-81. DOI: 10.1016/j.cgh.2006.02.005. View

Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A . Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006; 24(24):3946-52. DOI: 10.1200/JCO.2005.05.1490. View

Artinyan A, Soriano P, Prendergast C, Low T, Ellenhorn J, Kim J . The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB (Oxford). 2008; 10(5):371-6. PMC: 2575681. DOI: 10.1080/13651820802291233. View

Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R . Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2012; 31(1):23-9. DOI: 10.1200/JCO.2012.44.4869. View

Porta M, Fabregat X, Malats N, Guarner L, Carrato A, De Miguel A . Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol. 2005; 7(5):189-97. DOI: 10.1007/BF02712816. View

Brentnall T . Pancreatic cancer surveillance: learning as we go. Am J Gastroenterol. 2011; 106(5):955-6. DOI: 10.1038/ajg.2011.68. View

Ruckert F, Pilarsky C, Grutzmann R . Serum tumor markers in pancreatic cancer-recent discoveries. Cancers (Basel). 2013; 2(2):1107-24. PMC: 3835121. DOI: 10.3390/cancers2021107. View

10.

Duffy M, Sturgeon C, Lamerz R, Haglund C, Holubec V, Klapdor R . Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2009; 21(3):441-447. DOI: 10.1093/annonc/mdp332. View

11.

Miura F, Takada T, Amano H, Yoshida M, Furui S, Takeshita K . Diagnosis of pancreatic cancer. HPB (Oxford). 2008; 8(5):337-42. PMC: 2020745. DOI: 10.1080/13651820500540949. View

12.

Ausania F, Cook N, Jamieson N, Huguet E, Jah A, Praseedom R . Impact of pancreatic leaks on survival following pancreaticoduodenectomy. JOP. 2010; 11(3):226-9. View

13.

Jones S, Hruban R, Kamiyama M, Borges M, Zhang X, Parsons D . Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009; 324(5924):217. PMC: 2684332. DOI: 10.1126/science.1171202. View

14.

Slater E, Langer P, Fendrich V, Habbe N, Chaloupka B, Matthai E . Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Fam Cancer. 2010; 9(3):335-43. DOI: 10.1007/s10689-010-9329-6. View

15.

Berlin J, Catalano P, Thomas J, Kugler J, Haller D, Benson 3rd A . Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002; 20(15):3270-5. DOI: 10.1200/JCO.2002.11.149. View

16.

Neoptolemos J, Stocken D, Tudur Smith C, Bassi C, Ghaneh P, Owen E . Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer. 2009; 100(2):246-50. PMC: 2625958. DOI: 10.1038/sj.bjc.6604838. View

17.

Petersen G, de Andrade M, Goggins M, Hruban R, Bondy M, Korczak J . Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 2006; 15(4):704-10. DOI: 10.1158/1055-9965.EPI-05-0734. View

18.

Woodmass J, Lipschitz J, McKay A . Physician attitudes and treatment patterns for pancreatic cancer. World J Surg Oncol. 2011; 9:21. PMC: 3049185. DOI: 10.1186/1477-7819-9-21. View

19.

Neoptolemos J, Stocken D, Bassi C, Ghaneh P, Cunningham D, Goldstein D . Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010; 304(10):1073-81. DOI: 10.1001/jama.2010.1275. View

20.

Moore M, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S . Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(15):1960-6. DOI: 10.1200/JCO.2006.07.9525. View